Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 12/03 12:29:12 pm
300.195 USD   -0.43%
12:15pVaccine makers could make Omicron-specific booster, says Fauci
RE
12:02pPUMP / DUMP #13 : This week's gainers and losers
01:21aUK jabs deal to 'future-proof' immunisation
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : EU regulator verdict on Moderna COVID-19 booster shot next week

10/21/2021 | 08:11am EST

LONDON, Oct 21 (Reuters) - The European Union's drug regulator expects to announce the results of its review of Moderna's COVID-19 booster vaccine next week and also to start a rolling review of Merck's antiviral oral pill, a senior official said on Thursday.

The results of the Moderna review will be announced on Oct. 25, Marco Cavaleri, head of vaccines strategy for the European Medicines Agency (EMA), told a briefing.

Cavaleri also said it was not clear whether Russia would submit an application for its one-dose coronavirus vaccine, known as Sputnik Light, in addition to one already submitted for its two-dose Sputnik V shot.

"We don't have really any clear understanding of whether (the Russian team) intends to submit an application also for this vaccine in the European Union, but we will continue the dialogue to get more clarity on this," he said.

The start of a formal review of the two-dose Sputnik V was confirmed in March https://www.reuters.com/article/us-health-coronavirus-europe-vaccines-idUSKCN2AW0W8, but no decision has yet been announced.

Reuters reported on Thursday that the regulator was unlikely to decide whether to approve the Russian vaccine until at least the first quarter of 2022 because it still lacked some data required for the review.

This is in line with what the World Health Organization has said regarding delays in its Emergency Use Listing process.

BOOSTERS AND PILLS

The EMA's conclusion on boosters of Moderna's vaccine, Spikevax, is expected for use in people over 12 years of age and the shot is to be given six months after a second dose.

The EMA said it expected to receive data on boosters of the single-shot Johnson & Johnson vaccine in the coming weeks.

On Oct. 4, the watchdog gave the go-ahead for the Pfizer-BioNTech boosters and recommended a third dose of a shot from Pfizer-BioNTech or Moderna for vulnerable people, leaving it to member states to decide for the rest.

U.S. authorities have authorised on Wednesday booster doses of Pfizer-BioNTech, Moderna and J&J.

While vaccines are the main weapon against COVID-19, Merck's experimental pill, which it is developing with partner Ridgeback Biotherapeutics, could be a game-changer after studies showed it could halve the chances of dying or being hospitalised for those most at risk of contracting severe illness.

Britain has already secured a deal https://www.reuters.com/world/uk/britain-secures-covid-19-antivirals-merck-pfizer-2021-10-20 for the drug, molnupiravir, well before any approvals.

(Reporting by Josephine Mason in London and Pushkala Aripaka in Bengaluru; Editing by Jason Neely, Edmund Blair and Gareth Jones)


ę Reuters 2021
All news about MODERNA, INC.
12:15pVaccine makers could make Omicron-specific booster, says Fauci
RE
12:02pPUMP / DUMP #13 : This week's gainers and losers
01:21aUK jabs deal to 'future-proof' immunisation
AQ
12/02Pfizer-BioNTech, Moderna's COVID-19 Jabs Offer Best Immunity Boost, UK Study Says
MT
12/02U.S. administers 464.4 mln doses of COVID-19 vaccines - CDC
RE
12/02U.S. CDC Says Delivered 578,263,565 Doses Of COVID-19 Vaccine As Of Dec 2
RE
12/02US Stocks Rebound Following Recent Sell-Offs as Omicron Variant Concerns Subside
MT
12/02Stocks Led Higher Midday by Financials, Energy; GlaxoSmithKline Says Sotrovimab Showed ..
MT
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/02COVID-19 vaccines less effective in cancer patients receiving chemotherapy
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 11,5x
Yield 2021 -
Capitalization 122 B 122 B -
EV / Sales 2021 6,30x
EV / Sales 2022 4,82x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 301,49 $
Average target price 272,53 $
Spread / Average Target -9,60%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-40.67%24 745
ICON PUBLIC LIMITED COMPANY40.04%22 226